Results 91 to 100 of about 18,542 (210)

Effects of galantamine on attention and memory in Alzheimer's disease measured by computerized neuropsychological tests: results of the Brazilian Multi-Center Galantamine Study (GAL-BRA-01) Efeitos da galantamina sobre a memória e a atenção na doença de Alzheimer medidos por testes neuropsicológicos computadorizados: resultados do Estudo Multicêntrico com Galantamina (GAL-BRA-01)

Arquivos de Neuro-Psiquiatria, 2004
OBJECTIVE: To investigate the effects of galantamine on the performance of patients with mild to moderate Alzheimer's disease (AD) in a computerized neuropsychological test battery (CNTB).
Paulo Caramelli, Márcia L.F. Chaves, Eliasz Engelhardt, João Carlos B. Machado, Rodrigo R. Schultz, Francisco A.C. Vale, Helenice Charchat-Fichman   +6 more
doaj   +1 more source

Cross-cultural adaptation of the disability assessment for dementia (DAD) [PDF]

, 2007
The original version of the Disability Assessment for Dementia (DAD) was translated into Portuguese and back translated to English. The divergences of translation were identified and discussed, resulting in a version that was used in a preliminary ...
Areza-fegyveres, Renata, Bertolucci, Paulo Henrique Ferreira, Caramelli, Paulo, Carthery-goulart, Maria Tereza, Nitrini, Ricardo, Okamoto, Ivan, Schultz, Rodrigo R.   +6 more
core   +2 more sources

Galantamine as a Potential Treatment for Peripheral Nerve Injuries: Emphasis on Non-Systemic Delivery

Future Pharmacology
Peripheral nerve injuries can lead to significant functional impairments, and treatment options remain limited. Galantamine, widely used for cognitive disorders, has shown potential effects on the peripheral nervous system, making it a candidate for new ...
Mariya Ivanova, Liliya Panayotova-Ovcharova, Detelina Nedyalkova-Petkova, Petar Petkov, Georgi Boshev, Evgeniya Vladeva   +5 more
doaj   +1 more source

Development of transfersomal buccal patches of galantamine for enhanced bioavailability in Alzheimer’s disease therapy

Journal of Applied Pharmaceutical Research
Background: Galantamine, an acetylcholinesterase inhibitor used in Alzheimer’s disease, exhibits low and variable bioavailability due to gastrointestinal metabolism and first-pass hepatic elimination. Buccal drug delivery offers a non-invasive route that
Pavuluri Chandrasekhar, Rajaganapathy Kaliyaperumal   +1 more
doaj   +1 more source

Sleep and memory problems: acetylcholine in some neurodegenerative diseases, use of an extended-release formulation of galantamine

Неврология, нейропсихиатрия, психосоматика, 2012
The paper reviews the literature dedicated to an association between sleep and memory problems and acetylcholine (AC) levels. Moderate impairments of circadian rhythms can develop with aging; however, these changes become quite significant in dementia ...
I V Litvinenko
doaj   +1 more source

Validity, Significance, Strengths, Limitations, and Evidentiary Value of Real-World Clinical Data for Combination Therapy in Alzheimer's Disease: Comparison of Efficacy and Effectiveness Studies [PDF]

, 2014
Background: Randomized controlled efficacy trials (RCTs), the scientific gold standard, are required for regulatory approval of Alzheimer's disease (AD) interventions, yet provide limited information regarding real-world therapeutic effectiveness ...
Atri, Alireza, Doody, Rachelle S., Lopez, Oscar L., Rountree, Susan D.   +3 more
core   +1 more source

Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil

Neuropsychiatric Disease and Treatment, 2013
Osamu Kano,1 Hirono Ito,1 Takanori Takazawa,1 Yuji Kawase,1 Kiyoko Murata,1 Konosuke Iwamoto,1 Tetsuro Nagaoka,1 Takehisa Hirayama,1 Ken Miura,1 Riya Nagata,1 Tetsuhito Kiyozuka,2 Jo Aoyagi,2 Ryuta Sato,2 Teruo Eguchi,3 Ken Ikeda,1 Yasuo ...
Kano O, Ito H, Takazawa T, Kawase Y, Murata K, Iwamoto K, Nagaoka T, Hirayama T, Miura K, Nagata R, Kiyozuka T, Aoyagi J, Sato R, Eguchi T, Ikeda K, Iwasaki Y   +15 more
doaj  

Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs

Molecules, 2017
The actions of many drugs involve enzyme inhibition. This is exemplified by the inhibitors of monoamine oxidases (MAO) and the cholinsterases (ChE) that have been used for several pharmacological purposes.
Rona R. Ramsay, Keith F. Tipton
doaj   +1 more source

2026 Alzheimer's disease facts and figures

Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.
Abstract This article describes the public health impact of Alzheimer's disease (AD), including prevalence and incidence, mortality and morbidity, use and costs of care, and the ramifications of AD for family caregivers, the dementia workforce, and society.
wiley   +1 more source

Prior Authorization as a Potential Support of Patient-Centered Care. [PDF]

, 2018
We discuss the role of prior authorization (PA) in supporting patient-centered care (PCC) by directing health system resources and thus the ability to better meet the needs of individual patients. We begin with an account of PCC as a standard that should
Berger, Zackary, Rand, Leah
core